Company Overview
Snapshot
Founded in December 2020 by Peter Siman, Avner Geva, and Avi Domb, IntraGel Therapeutics operates with 1-10 employees. The company has raised $450,000 across three funding rounds from three investors. In May 2023, IntraGel Therapeutics secured pre-seed funding from the Israel Innovation Authority and NGT HealthCare II.
Business overview
IntraGel Therapeutics is a research-driven company focused on developing advanced treatments for solid tumors. The company's core product, TumoCure, utilizes its proprietary SRGel platform, a gel-based drug delivery technology designed for local and prolonged release of anti-cancer medications directly at the tumor site. This approach aims to maximize therapeutic effectiveness while minimizing systemic exposure and adverse effects. The SRGel platform, built on natural and safe fatty acids, is an injectable, pre-filled single syringe, making it easy to administer in various solid tumors, including those that are surgically inaccessible or chemo/radio-resistant. IntraGel Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drug Delivery markets.
Strategic signal
In August 2023, IntraGel Therapeutics was actively raising an additional $5 million to secure FDA approval for a Phase II clinical trial for its flagship product, TumoCure. This fundraising effort, following an earlier $2 million raise, signals the company's commitment to advancing its gel-based drug delivery platform for solid tumors and indicates a clear path toward significant clinical validation and potential market entry. The company's advanced collaborations with leading global pharmaceutical companies also suggest strong strategic interest and potential for future acquisition, positioning IntraGel Therapeutics as a high-potential asset in the oncology drug delivery space.
Log in to access full profile ›Company Intelligence Q&A
- When was IntraGel Therapeutics founded and by whom?
- IntraGel Therapeutics was founded in December 2020 by Peter Siman, Avner Geva, and Avi Domb.
- What is IntraGel Therapeutics' primary product?
- IntraGel Therapeutics' primary product is TumoCure, which utilizes the SRGel platform for localized drug delivery in solid tumors.
- What was a key funding event for IntraGel Therapeutics in 2023?
- In May 2023, IntraGel Therapeutics secured pre-seed funding from the Israel Innovation Authority and NGT HealthCare II.
- What is the strategic significance of IntraGel Therapeutics' ongoing fundraising efforts?
- In August 2023, IntraGel Therapeutics was raising an additional $5 million to fund FDA approval for a.
- What is the company's current employee count?
- IntraGel Therapeutics currently has 1-10 employees.